328 related articles for article (PubMed ID: 34717972)
1. Allosteric Regulation of 3CL Protease of SARS-CoV-2 and SARS-CoV Observed in the Crystal Structure Ensemble.
Kidera A; Moritsugu K; Ekimoto T; Ikeguchi M
J Mol Biol; 2021 Dec; 433(24):167324. PubMed ID: 34717972
[TBL] [Abstract][Full Text] [Related]
2. Optimization of quenched fluorescent peptide substrates of SARS-CoV-2 3CL
Cesar Ramos de Jesus H; Solis N; Machado Y; Pablos I; Bell PA; Kappelhoff R; Grin PM; Sorgi CA; Butler GS; Overall CM
J Virol; 2024 Jun; 98(6):e0004924. PubMed ID: 38742901
[TBL] [Abstract][Full Text] [Related]
3. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL
Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ
Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621
[TBL] [Abstract][Full Text] [Related]
4. Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations.
Ahmad B; Batool M; Ain QU; Kim MS; Choi S
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502033
[TBL] [Abstract][Full Text] [Related]
5. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.
Tomar S; Johnston ML; St John SE; Osswald HL; Nyalapatla PR; Paul LN; Ghosh AK; Denison MR; Mesecar AD
J Biol Chem; 2015 Aug; 290(32):19403-22. PubMed ID: 26055715
[TBL] [Abstract][Full Text] [Related]
6. Mutation of Gly-11 on the dimer interface results in the complete crystallographic dimer dissociation of severe acute respiratory syndrome coronavirus 3C-like protease: crystal structure with molecular dynamics simulations.
Chen S; Hu T; Zhang J; Chen J; Chen K; Ding J; Jiang H; Shen X
J Biol Chem; 2008 Jan; 283(1):554-564. PubMed ID: 17977841
[TBL] [Abstract][Full Text] [Related]
7. Structure-based virtual screening suggests inhibitors of 3-Chymotrypsin-Like Protease of SARS-CoV-2 from Vernonia amygdalina and Occinum gratissimum.
Gyebi GA; Elfiky AA; Ogunyemi OM; Ibrahim IM; Adegunloye AP; Adebayo JO; Olaiya CO; Ocheje JO; Fabusiwa MM
Comput Biol Med; 2021 Sep; 136():104671. PubMed ID: 34332348
[TBL] [Abstract][Full Text] [Related]
8. Combining Different Docking Engines and Consensus Strategies to Design and Validate Optimized Virtual Screening Protocols for the SARS-CoV-2 3CL Protease.
Manelfi C; Gossen J; Gervasoni S; Talarico C; Albani S; Philipp BJ; Musiani F; Vistoli G; Rossetti G; Beccari AR; Pedretti A
Molecules; 2021 Feb; 26(4):. PubMed ID: 33557115
[TBL] [Abstract][Full Text] [Related]
9. Discovery of New Hydroxyethylamine Analogs against 3CL
Kumar S; Sharma PP; Shankar U; Kumar D; Joshi SK; Pena L; Durvasula R; Kumar A; Kempaiah P; Poonam ; Rathi B
J Chem Inf Model; 2020 Dec; 60(12):5754-5770. PubMed ID: 32551639
[TBL] [Abstract][Full Text] [Related]
10. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
11. Rapid peptide-based screening on the substrate specificity of severe acute respiratory syndrome (SARS) coronavirus 3C-like protease by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
Chu LH; Choy WY; Tsai SN; Rao Z; Ngai SM
Protein Sci; 2006 Apr; 15(4):699-709. PubMed ID: 16600962
[TBL] [Abstract][Full Text] [Related]
12. Novel inhibitors of the main protease enzyme of SARS-CoV-2 identified via molecular dynamics simulation-guided in vitro assay.
Loschwitz J; Jäckering A; Keutmann M; Olagunju M; Eberle RJ; Coronado MA; Olubiyi OO; Strodel B
Bioorg Chem; 2021 Jun; 111():104862. PubMed ID: 33862474
[TBL] [Abstract][Full Text] [Related]
13. Structural and functional significance of the amino acid differences Val
Denesyuk AI; Permyakov EA; Johnson MS; Permyakov SE; Denessiouk K; Uversky VN
Int J Biol Macromol; 2021 Dec; 193(Pt B):2113-2120. PubMed ID: 34774600
[TBL] [Abstract][Full Text] [Related]
14. Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing.
Pathak N; Chen YT; Hsu YC; Hsu NY; Kuo CJ; Tsai HP; Kang JJ; Huang CH; Chang SY; Chang YH; Liang PH; Yang JM
ACS Nano; 2021 Jan; 15(1):857-872. PubMed ID: 33373194
[TBL] [Abstract][Full Text] [Related]
15. Flavonoids in Ampelopsis grossedentata as covalent inhibitors of SARS-CoV-2 3CL
Xiong Y; Zhu GH; Zhang YN; Hu Q; Wang HN; Yu HN; Qin XY; Guan XQ; Xiang YW; Tang H; Ge GB
Int J Biol Macromol; 2021 Sep; 187():976-987. PubMed ID: 34333006
[TBL] [Abstract][Full Text] [Related]
16. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC
J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022
[TBL] [Abstract][Full Text] [Related]
17. Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CL
Rawson JMO; Duchon A; Nikolaitchik OA; Pathak VK; Hu WS
Viruses; 2021 Jan; 13(2):. PubMed ID: 33498923
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 3CL
Kuo CJ; Liang PH
FEBS Lett; 2022 May; 596(9):1214-1224. PubMed ID: 35302661
[TBL] [Abstract][Full Text] [Related]
19. Visualizing the Active Site Oxyanion Loop Transition Upon Ensitrelvir Binding and Transient Dimerization of SARS-CoV-2 Main Protease.
Kovalevsky A; Aniana A; Coates L; Ghirlando R; Nashed NT; Louis JM
J Mol Biol; 2024 Jul; 436(13):168616. PubMed ID: 38762033
[TBL] [Abstract][Full Text] [Related]
20. Ensemble Docking Coupled to Linear Interaction Energy Calculations for Identification of Coronavirus Main Protease (3CL
Jukič M; Janežič D; Bren U
Molecules; 2020 Dec; 25(24):. PubMed ID: 33316996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
